rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Arbutus Biopharma Corporation

ABUS · Nasdaq

Health CareBiotechnologyNot moving yet

ABUS stood above a rising 150-day average in 26 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 7.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
170 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$242K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders170+12 on the quarter
New · exited33 · 22
Reported value$678.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Two Seas Capital LPadded · filed 12 Aug 202619,095,583$91.7M+538,040+2.9%
MORGAN STANLEYreduced · filed 13 Aug 202617,698,305$85.0M-8,193,175−31.6%
Whitefort Capital Management, LPadded · filed 14 Aug 202615,794,261$75.8M+863,376+5.8%
BlackRock, Inc.added · filed 7 Aug 202613,766,071$66.1M+799,125+6.2%
STATE STREET CORPadded · filed 7 Aug 20267,869,179$37.8M+1,526,669+24.1%
Rubric Capital Management LPadded · filed 14 Aug 20267,532,937$36.2M+906,548+13.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,010,679$33.7M+321,768+4.8%
BARCLAYS PLCreduced · filed 14 Aug 20264,207,914$20.2M-108,181−2.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,117,691$19.8M+345,885+9.2%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20263,506,802$16.8M+2,406,368+218.7%
31 Mar 2023 – 30 Jun 2026
89128167Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Lindsay Androski Company insiderPresident and CEO · last 1 Oct 20260 · 0
Robert A. Beardsley Company insiderDirector · last 1 Oct 20260 · 0
Roger Sawhney Company insiderDirector · last 1 Oct 20260 · 0
Roivant Sciences Ltd. Company insiderDirector, 10% owner · last 1 Oct 20260 · 0
Tuan Nguyen Company insiderChief Financial Officer · last 1 Oct 20260 · 0
Anuj Hasija Company insiderDirector · last 18 Mar 20250 · 0
David C. Hastings Company insiderChief Financial Officer · last 14 Feb 20250 · 2
J. Christopher Naftzger Company insiderGeneral Counsel and CCO · last 14 Feb 20250 · 1
Karen Sims Company insiderChief Medical Officer · last 14 Feb 20250 · 2
Michael J. McElhaugh Company insiderInterim President & CEO · last 14 Feb 20250 · 5
Keith S. Manchester Company insiderDirector · last 14 Aug 20240 · 1
Daniel D. Burgess Company insiderDirector · last 23 May 20240 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$52.2M
Latest14 Jul 2010

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-271%
Free cash flow marginFY 2025 · to 31 Dec 2025-281%
Return on capital employedFY 2025 · to 31 Dec 2025-43.1%
Research spendFY 2025 · to 31 Dec 2025179%
Share count trendFY 2025 · to 18 Mar 20261.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$18.0M
Free cash flowFY 2025 · to 31 Dec 2025−$39.6M

Analyst forecasts

No analyst forecasts yet.